When the cut-off value was set at 0.91 mg/L, the positive rate (serum anti-PLA2R-IgG > 0.91 m﻿g/L) in patients with IMN was 84.06%, followed by minimal change disease (58.33%), lupus nephritis (50%), IgA nephropathy (41.82%), and other nephropathy (40%). Here, PLA2R1 is linked to Nephropathy.